Doctors at Weill Cornell Medical Center in October performed a cesium-131 implant for the treatment of colorectal cancer, according to medical isotope developer IsoRay Medical of Richland, WA.
The implant was performed on a 38-year-old patient with locally recurrent colon cancer. Cornell doctors chose cesium-131 for its short half-life and higher dose rate, as well as its relative safety to medical staff (because of faster radioactive dose fall-off) if the patient requires additional medical care soon after the implant, IsoRay said.
IsoRay is the sole producer of the cesium-131 brachytherapy seed, the company said. It plans to open a lung study in early 2010 and move forward with preparations to expand the use of cesium-131 to additional areas in the body.
Related Reading
IsoRay inks distribution deal with Oncura, December 4, 2009
IsoRay adds Canadian distributor, November 18, 2009
IsoRay touts cesium-131 treatment, September 28, 2009
IsoRay's 2009 results dip, September 24, 2009
IsoRay nets FDA OK on seeds, August 18, 2009
Copyright © 2010 AuntMinnie.com
